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Abstract
Aims-To examine long term survival of
women with primary and recurrent cervi-
cal carcinoma in relation to (1) excretion
of P-core (a urinary metabolite of P
human chorionic gonadotrophin (PhCG))
and (2) PhCG immunostaining of the
tumours, to determine the suitability of
these markers for assessing prognosis.
Methods-This was a prospective obser-
vational study undertaken in a gynaeco-
logical oncology centre: 57 women with
primary cervical cancer and 42 with
recurrent disease were recruited between
January 1990 and September 1992.
Kaplan-Meier survival analysis with the
log rank test was used to assess survival
differences with survival rate given per
year of follow up.
Results-In primary disease, the four year
survival for the P-core negative group was
79%, compared with 14% for the P-core
positive group (p = 0.001). This was still
significant for early stage disease or
squamous lesions alone. In recurrent dis-
ease, P-core positivity was not prognosti-
cally significant. Immunohistochemistry
was ofno prognostic significance in either
group.
Conclusions-p-core excretion appears to
be useful in assessing prognosis of pri-
mary cervical cancer but not of recurrent
disease. A large prospective study of
urinary P-core in early stage cervical can-
cer is needed to determine whether it can
be used as an index for modifying treat-
ment.
( Clin Pathol 1998;51:685-688)
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Human chorionic gonadotrophin (hCG) is a
valuable tumour marker for trophoblastic
disease and germ cell tumours. In addition,
synthesis of free PhCG and its subunits by pel-
vic carcinomas such as those of the colon,' uri-
nary tract,2 prostate,3 uterus,4 and vulvo-
vagina5 has been reported. The presence of
increased serum levels of hCG and its metabo-
lites is generally agreed to be a sign of a poor
prognosis` and it has been suggested that
[3hCG might directly modify the growth of the
cancer, leading to a worse outcome.6 Further-
more, positive immunohistochemical staining
for 3hCG is also associated with a survival dis-
advantage following radiotherapy.9
However, the clinical use of free PhCG as a
tumour marker has been limited to a small
number of patients owing to a short half life
and rapid renal clearance. Attention has there-
fore been focused on urine metabolites, in par-
ticular [-core,'0 which is produced as a result of
the intrarenal metabolism of [hCG. The
majority of hCG immunoreactivity in urine is
accounted for by [B-core. Excess P-core is asso-
ciated with gynaecological cancer (reviewed by
Cole et at). In a previous study from our
group," we reported that [-core was a
significant prognostic indicator for premeno-
pausal women with primary cervical cancer
followed up for only 18 months.
We now report the long term outcome of a
group of patients with primary and recurrent
cervical cancer in relation to urinary excretion
of [-core. Some of these patients were included
in our previous report." In addition, we report
the results of immunohistochemical staining of
the tumours for [hCG.
Methods
The study included consecutive patients pre-
senting with cervical cancer (primary and
recurrent) at St Bartholomew's Hospital and
the Royal Marsden Hospital between January
1990 and September 1992. Local research eth-
ics committees had approved the protocol.
Fifty seven women with primary disease and 42
with recurrent disease were identified. All
patients with recurrence had already received
pelvic radiotherapy. A representative block was
selected for each patient from archival tissue
and 3 ptm sections were mounted on coated
slides for immunohistochemistry. An adjacent
slide was stained with haematoxylin and eosin
for reference. The histological diagnosis was
reviewed by CJC.
fIhCG
Samples suitable for immunohistochemistry
were available from 46 patients with primary
cervical cancer and from 29 with recurrent dis-
ease. For immunohistochemistry, sections were
dewaxed and then pressure cooked for four
minutes at 103 kPa'2 as the method of antigen
enhancement. A rabbit polyclonal anti-PhCG
antibody (Dako, High Wycombe, UK) was
used at a dilution at 1/5000 overnight at 40C. A
standard indirect avidin-biotin immunoperoxi-
dase technique was then applied. A section of
placenta was used a positive control, and the
primary antibody was substituted with non-
specific rabbit antibody as negative control.
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Figure 1 Kaplan-Meier survival curve for patients
presenting with primary cervical cancer separated on the
basis of the urinary f-core measured at presentation (log
rank test: X2d, = 19. 74;p = 0. 001). f-Core negative
group: n = 30; six events;five year survival 79%. fl-Core
positive group: n = 14; 11 events; median survival 12
months,fouryear survival 14%.
The slides were scored visually by two inde-
pendent observers (RAFC, CJC) for granular
cytoplasmic staining. The case was scored
positive if any tumour cell showed positive
staining.
P-CORE ESTIMATION
All women provided a urine sample at their
initial attendance. Specimens with a creatinine
concentration greater than 4 mmol/litre were
assayed for P-core as described"; values were
considered raised if they were above the 90th
centile for the relevant group (premenopausal
0.034 ng 1-core/ml/mmol creatinine; post-
menopausal 0.094 ng 1-core/ml/mmol creati-
nine). Forty six women with primary disease
and 38 women with recurrent cervical cancer
had sufficiently concentrated urine for P-core
estimation.
PATIENT CHARACTERISTICS
Primary cervical cancer
The median age of the group was 43 years
(range 23 to 82 years) and 35 women were
premenopausal. There was no age related sur-
vival advantage in this group of women
comparing young women (< 40 years) with
older women, nor any relation to menopausal
status. There were 28 cases with stage 1
disease, 11 with stage 2, 10 with stage 3, five
with stage 4, and no record in three cases. Forty
cases were squamous cell carcinoma, eight
were adenocarcinoma, and seven had adeno-
squamous lesions (identified with periodic acid
Schiff and alcian blue (PAS/AB) staining in
addition to H&E). In two cases the pathology
was not recorded. The median time to death or
date of census (April 1996) was 35 months
(range 1 to 74 months). Follow up information
was not available in two cases.
Recurrent cervical cancer
The median age of this group was 45 years
(range 25 to 78 years). The median survival
from initial diagnosis of cancer was 22 months
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Figure 2 Kaplan-Meier survival curve for patients
presenting with primary cervical cancer separated on the
basis of f-core and stage (log rank test:/ = 28. 52;p =
0. 001). fl-Core negativelearly stage: n =0; one event;five
year survival 95%;,f-core negativellate stage: n = 10;five
events; median survival 37 months. #-Core positivelearly
stage: n = 3; three events; median survival eight months;
fl-core positivellate stage: n = 11; eight events; median
survival 12 months.
(range 2 to 149 months). At initial diagnosis,
there were 19 cases with stage 1 disease, 13
with stage 2, five with stage 3, four with stage 4,
and no record of initial stage in one case.
Thirty cases were squamous cell carcinoma,
five were adenocarcinoma, and five had ad-
enosquamous lesions. The original histology
was not recorded in one case. The median sur-
vival time from diagnosis of recurrent cancer,
when the urine marker was investigated, was
eight months (range 1 to 71 months). The five
year survival of this group from presentation
with recurrent cervical cancer was 10%.
STATISTICS
The percentage survival for each group was
calculated using the Kaplan-Meier method
and comparisons between groups were per-
formed using the log-rank test (SPSS for Win-
dows, 6.1.3 1995). Where data did not extend
to five years, survival rate is given per year of
follow up in that group.
Results
PRIMARY DISEASE
Thirty one patients were ,B-core negative and
15 were 1-core positive. The four year survival
for women who were ,8-core negative was 79%;
the four year survival of the J-core positive
women was only 14% (log rank test: X2df=l
=19.74; p = 0.001) (fig 1). This survival differ-
ence was also seen when early (stage 1) and late
stage (stage 2 and more advanced) disease was
compared (five year survival for 13-core negative
and early stage, 95%; median survival for
1-core negative and late stage, 37%; no
survivors at one year for ,B-core positive and
early stage, median survival eight months;
median survival for [3-core positive and late
stage, 12%; log rank test: X2df-3 = 28.52; p =
0.001) (fig 2). Women with squamous lesions
also showed a significant survival advantage in
the [-core negative group (two and four year
survival for [-core negative women 79%, v
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30% in 1-core positive women (log rank test:
x2df= = 14.2; p = 0.001). Thirty four patients
had PhCG negative tumours on immunohisto-
chemistry and 12 were positive. In the cases
with positive immunohistochemistry, small
numbers of tumour cells (< 5%) showed cyto-
plasmic staining. The assessment of PhCG
staining was not prognostic on its own and did
not contribute to the significance of the urine
P-core marker.
RECURRENT DISEASE
Nineteen women had negative urine P-core
results at the time of presentation with
recurrence and 19 were positive. The 1-core
values at the time of presentation were of no
prognostic significance. The percent 1-core
positivity (50%) of this group was not signifi-
cantly higher than that in the primary presen-
tation group (33%; X2df=l = 2.6; p = 0.1).
Nineteen cases were 13hCG negative by immu-
nohistochemistry from material collected at the
time of the recurrence and 10 were positive. In
this group, immunohistochemistry was of no
prognostic significance, either alone or in com-
bination with P-core.
Discussion
Our previous study'" showed that 1-core is a
useful short term prognostic marker in primary
cervical cancer (18 months of follow up). Our
present report now extends and confirms these
findings with a larger group and longer follow
up period. This is particularly important in
cervical carcinoma, as most recurrences (treat-
ment failure and persistent disease) will
present within the first two years'3 14 and so
may have been missed in the earlier study.
In the group of women who had recurrent
disease, 1-core was of no prognostic value. As
the recurrent group is a selected subset with a
very poor outcome, the higher number of posi-
tives is not unexpected. The phenomenon may
be related to alterations in tumour biology
associated with advanced disease or it may be
attributable to previous treatment, for example
radiotherapy. Reduced vascularity of irradiated
areas containing tumour may have led to
reduced amounts of 1-core in the urine. In this
study it was not possible to determine whether
patients who were 1-core positive at recurrence
had been persistently 1-core positive or
whether this was a new phenomenon associ-
ated with disease recurrence and poor out-
come. Cell culture has shown a positive growth
effect of free ,BhCG on cervical cancer cell lines
(Crawford RAF, unpublished data) suggesting
that a change in the local environment may
lead to increasing aggressiveness. The five year
survivors in the recurrent disease group were
mostly those who had had pelvic exenteration.
In contrast to the earlier study," there was no
difference in outcome related either to meno-
pausal status or to age (above or below 40
years). The presence of high levels of luteinis-
ing hormone 13-core fragment in postmenopau-
sal urine" 1 and its cross reactivity with the
antibody to 1-core derived from 13hCG has
been accounted for by using cut off limits
appropriate for age and menopausal status.
The urine samples of 11 of the 57 patients with
primary cancer and four of the 42 patients with
recurrent cancer were too dilute for 1-core
analysis. This may have introduced bias, but as
the samples were analysed in batches it was not
possible to collect further specimens from
these patients.
A tissue specimen is always taken at the time
of diagnosis of primary and recurrent disease.
The presence of 1hCG can be detected using
immunohistochemistry and might obviate the
need for a urine test (13-core). However, in the
present study PhCG staining was of no
prognostic value in any group. This might be
related to technical problems, although we used
an appropriate antigen retrieval method.'2 The
more likely explanation is that ,BhCG is released
rapidly following synthesis with little or no stor-
age in the cell, and a random section of the
tumour will be unlikely to contain more than a
few positive cells at most. The small amount of
staining in cases which were counted as positive
is in contrast to positive transitional cell bladder
carcinomas which show widespread staining.
This suggests that the positive areas might rep-
resent non-specific staining. In colorectal can-
cer, the prognostic significance of raised serum
13hCG as a tumour marker was significant for
poor outcome8 while immunohistochemical
staining was of no value.'7 These findings are
reflected in our study.
The expression of PhCG is stage related.4
Two of the three women who were 1-core posi-
tive in the early stage subset of the primary
group had involved pelvic lymph nodes.
Therefore, larger numbers are required to
determine whether the 1-core expression and
poor outcome are related to a larger tumour
volume rather than to more aggressive disease.
With the increased effectiveness of the United
Kingdom national cervical screening pro-
gramme, there has been a considerable fall in
mortality and a reduction in the frequency of
advanced disease.'8 In advanced stage disease,
the treatment options are limited to radio-
therapy with or without adjuvant chemo-
therapy. Only in early stage disease, however, is
there a significant potential for treatment
modification, with tailoring the extent of
surgery to suit the individual case with its
prognostic indicators. In the woman with an
early stage cancer and negative 1-core, consid-
eration may be given to a fertility sparing type
procedure if indicated. In those women with
positive 1-core, the use of chemo-radiotherapy
rather than surgery may be more appropriate.
A large prospective study of urinary 1-core in
early stage cervical cancer is needed to
ascertain whether it can be used as an index for
modifying treatment.
This study was supported by a grant from the Cancer Research
Committee, St Bartholomew's Hospital. Technical help with the
immunohistochemistry was provided by Mrs Suzanne Jordan.
Statistical advice was given by Ms Janice Thomas, Queen Mary
and Westfield College, University of London.
1 Campo E, Palacin A, Benasco C, et al. Human chorionic
gonadotrophin in colorectal carcinoma; an immunohisto-
chemical study. Cancer 1985:59:1611-16.
2 Iles RK, Jenkins BJ, Oliver RTD, et al. Beta human
chorionic gonadotrophin in serum and urine. A marker for
metastatic urothelial cancer. BrJ7 Urol 1989;64:241- 4.
687
Crawford, Iles, Carter, et al
3 Sheaff MT, Martin JE, Badenoch DF, et al. f3-hCG as a
prognostic marker in adenocarcinoma of the prostate.
Clin Pathol 1996;49:329-32.
4 Cole LA, Tanaka A, Kim GS, et al. [-Core fragment
(0-core/UGF/UGP), a tumor marker: a 7-year report.
Gynecol Oncol 1996;60:264-70.
5 Carter PG, Iles RK, Neven P, et al. Measurement of urinary
beta core fragment of human chorionic gonadotrophin in
women with vulvovaginal malignancy and its prognostic
significance. Br]7 Cancer 1995;71:350-3.
6 Iles RK, Chard T. Human chorionic gonadotrophin expres-
sion by bladder cancers: biology and clinical potential as an
indicator of poor prognosis. Urol 199 1;145:453-8.
7 Regelson W. Have we found the "definitive cancer" biomar-
ker? Cancer 1995;76:1299-301.
8 Carpelan-Holmstrom M, Haglund C, Lundin J, et al. Inde-
pendent prognostic value of pre-operative serum markers
CA 242, specific tissue polypeptide antigen and human
chorionic gonadotrophin beta, but not of carcinoembry-
onic antigen or tissue polypeptide antigen in colorectal
cancer. Br]7 Cancer 1996;74:925-9.
9 Moutzouris G, Yannopoulos D, Barbatis C, et al. Is
beta-human chorionic gonadotrophin production by tran-
sitional cell carcinoma of the bladder a marker of aggressive
disease and resistance to radiotherapy? Br]_ Urol 1993;72:
907-9.
10 Wehmann RE, Blithe DL, Flack MR, et al. Metabolic clear-
ance rate and urinary clearance of purified :-core. 7 Clin
Endocrinol Metab 1989;69:510- 17.
11 Carter PG, Iles RK, Neven P, et al. The prognostic
significance of urinary fcore fragment in premenopausal
women with carcinoma of the cervix. Gynecol Oncol
1994;55:271-6.
12 Norton AJ, Jordan S, Yeomans P. Brief, high-temperature
heat denaturation (pressure cooking): a simple and
effective method of antigen retrieval for routinely processed
tissues. Pathol 1994;173:371-9.
13 van Nagell JR, Rayburn WR, Donaldson ES, et al.
Therapeutic implications of patterns of recurrence in can-
cer of the uterine cervix. Cancer 1979,44:2354-61.
14 Look KY, Rocereto TF. Relapse patterns in FIGO stage 1B
carcinoma of the cervix. Gynecol Oncol 1990;38: 114-20.
15 Akar AH, Gervasi G, Blacker C, et al. Human chorionic
gonadotrophin-like and f-core-like materials in post-
menopausal urine. Endocrinol 1990;125:477-84.
16 Iles RK, Lee CL, Howes I, et al. Immunoreactive [-core-like
material in normal postmenopausal urine: human chori-
onic gonadotrophin or LH origin? Evidence for existence
of LH core.] Endocrinol 1992;133:459-66.
17 Webb A, Scott-Mackie P, Cunningham D, et al. The
prognostic value of CEA, beta hCG, AFP, CA 125, CA
19-9 and C-erb B-2, beta hCG immunohistochemistry in
advanced colorectal cancer. Ann Oncol 1995;6:581-7.
18 Sasieni P, Cuzick J, Farmery E. Accelerated decline in cervi-
cal cancer mortality in England and Wales. Lancet
1995;346:1566-7.
688
